Financial Times
GSK in talks to buy cancer biotech Nuvalent for more than $9bn
A deal will rank as one of UK drugmaker’s biggest as biotech M&A activity has enjoyed an upswing this year
View original source — Financial Times ↗
Related stories
CNBC
HealthJun 9, 2026 · 1 min
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
CNBC
Financial Times
HealthJun 19, 2026 · 1 min
AbbVie closes in on nearly $11bn deal for biotech Apogee Therapeutics
Financial Times
Bloomberg
HealthJun 9, 2026 · 1 min
GSK Agrees to Buy Nuvalent for $10.6 Billion
Bloomberg
The Guardian
HealthJun 9, 2026 · 1 min
GSK to buy US cancer treatment firm Nuvalent for $10.6bn
The Guardian